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1mpact of Ventricular
ssist Device Support
n Post-Transplant Mortality
earching for Reasons
ecently, Patlolla et al. (1) reported that ventricular assist devices
VADs) were associated with a significantly increased post-
ransplant mortality. The authors conclude that VAD implanta-
ion is not suitable for the treatment of stable patients awaiting
eart transplantation. We would like to congratulate the authors
n this study. However, in Germany, within the Eurotransplant
nternational Foundation network (2), the reality of organ shortage
nd waiting times may lead to other conclusions.
In our center we look back on almost 250 VAD implantations
f various intracorporeal and extracorporeal devices since 1993.
e share the opinion that VAD implantation is the treatment of
hoice for patients admitted as an emergency case (3). As a special
eature for the Eurotransplant situation, those patients recovering
rom VAD implantation are only accepted for high urgent status in
ase they develop serious problems associated with the device.
ince the request for organs oversteps the number of organ donors
y far, the waiting time for “regular patients” is often more than 2
ears, regardless of whether a VAD is present or not. Therefore, in
number of European countries (e.g., Germany) most patients are
ransplanted in the high urgent status (4), which is currently assigned
o more than 80% of all VAD patients in our center. Frankly, this
eans that a lot of VAD patients have to survive an emergency twice
ntil a suitable organ is offered. This situation is certainly an
mportant reason leading to increased mortality of heart transplanta-
ion after VAD implantation. However, a shortage of organs forces
hysicians to accept the increased risk associated with VADs.
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eply
e would like to thank Dr. Sindermann and colleagues for their
nterest in our paper (1). The decision to proceed with ventricular
ssist device (VAD) implantation in patients awaiting heart
ransplantation is complex. The factors that influence this decision
or a given patient include his or her anticipated rate of clinical
ecline, estimated time to availability of a donor organ, and
xpected survival in the absence of mechanical circulatory support.
ariations in organ allocation policies between different countries
lso may influence decisions regarding timing of VAD implanta-
ion and may lead to different outcomes after heart transplantation.
ince our analysis is based on a U.S. patient population, the
xplanations for our findings are best drawn from practice patterns
n the U.S. rather than in Europe.
In our analysis of United Network for Organ Sharing registry
ata, we were not able to demonstrate an improvement in
ost-transplant survival for patients bridged with a VAD. Our
ata, therefore, do not support the routine use of VAD therapy for
table United Network for Organ Sharing status 1 patients with
he primary goal of improving post-transplant survival. At our
nstitution, we limit the use of VADs as a bridge to transplant for
atients who exhibit refractory symptoms and/or evidence of
emodynamic compromise despite the use of intravenous inotro-
ic/vasodilator therapy.
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